Two Years of Evidence: What Trutakna's ORIGIN 3 Final Data Mean for IgA Nephropathy

IgA nephropathy has spent decades as one of nephrology's most frustrating problems. It is the most common primary glomerular disease in the world, affecting millions of people who are often diagnosed in their 30s and 40s, and it carries a sobering long-term prognosis: at least half of patients may progress to kidney failure or death within 10 to 20 years of diagnosis. Until recently, the treatment toolkit was thin. Now, in the span of roughly two years, the field has been transformed by a wave of approvals and late-stage data that is reshaping how nephrologists think about what is actually achievable in this disease.

On September 15, 2026, Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 Phase 3 trial, enrolling 428 adults with primary IgAN at risk for disease progression. The results were striking across every dimension the trial measured: eGFR was stabilized at a rate consistent with the KDIGO treatment goal of less than 1 mL/min/1.73m2 per year of decline, the composite risk of kidney disease progression was reduced by 76 percent, and statistically significant reductions were achieved in proteinuria, galactose-deficient IgA1, and hematuria. The safety profile was favorable and generally comparable to placebo, with no opportunistic infections and no clinically relevant hypogammaglobulinemia.

Why the Two-Year Timeframe Matters

The significance of the ORIGIN 3 final analysis is not just in the numbers. It is in what those numbers represent for the regulatory pathway. TRUTAKNA currently holds accelerated approval from the FDA, granted on the basis of proteinuria reduction as a surrogate endpoint. Accelerated approval is a conditional status: it requires a confirmatory trial demonstrating actual clinical benefit before full approval can be granted. The ORIGIN 3 final analysis is that confirmatory dataset, and hitting every prespecified endpoint in 428 patients over two years removes the largest near-term risk to the drug's commercial and regulatory position.

Vera Therapeutics has said it plans to submit a supplemental BLA to the FDA in the fourth quarter of 2026, with full approval potentially following in 2027. That timeline, if it holds, would convert TRUTAKNA from a conditionally approved therapy into one with a full regulatory endorsement backed by two years of hard clinical outcome data. For a disease where the standard of care has historically been limited to supportive measures and non-specific immunosuppression, that distinction carries real weight.

The eGFR stabilization finding deserves particular attention. Kidney function decline in IgAN is measured in milliliters per minute per year, and the difference between a drug that slows that decline and one that genuinely stabilizes it is not semantic. The KDIGO 2025 guidelines set a treatment goal of reducing the rate of kidney function decline to the physiologic rate, meaning the natural aging-related loss that occurs in healthy individuals. The ORIGIN 3 data suggest TRUTAKNA can achieve that benchmark in a meaningful proportion of patients, which is a different claim than simply reducing proteinuria or slowing progression modestly.

The Mechanism Behind the Results

TRUTAKNA works by blocking two cytokines simultaneously: BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). Both play central roles in the pathophysiology of IgAN. The disease is driven by a multi-hit process in which aberrantly glycosylated IgA1 antibodies form immune complexes that deposit in the kidney's glomeruli, triggering inflammation and progressive scarring. BAFF and APRIL sit upstream in this cascade, promoting the B cell activity that generates the pathogenic IgA1 in the first place. By targeting both simultaneously, TRUTAKNA aims to interrupt the disease at its immunological root rather than managing its downstream consequences.

This dual-inhibition approach distinguishes TRUTAKNA from several of its competitors in the IgAN space. Iptacopan (Fabhalta) targets the complement pathway. Sparsentan (Filspari) combines endothelin and angiotensin receptor antagonism. Sibeprenlimab (Voyxact) targets APRIL alone. Atrasentan (Vanrafia) is a selective endothelin A receptor antagonist. Each of these mechanisms addresses a different node in the IgAN disease process, and the field is increasingly moving toward a view that combination therapy, targeting multiple pathways simultaneously, may ultimately produce the best outcomes for patients with progressive disease.

A Crowded Field With Room for Differentiation

The IgAN treatment landscape has become genuinely competitive in a way that would have been unrecognizable five years ago. Four therapies have received FDA accelerated approval since 2024, and the confirmatory trial data are now beginning to arrive. Iptacopan's APPLAUSE-IgAN trial showed a statistically significant reduction in eGFR decline over two years, with an eGFR loss of 3 mL/min/1.73m2 per year in the treatment group compared with 6 mL/min/1.73m2 per year in the placebo group. The ORIGIN 3 data for TRUTAKNA appear to show eGFR stabilization at or near the physiologic rate, which would represent a more complete preservation of kidney function than what iptacopan demonstrated.

That comparison is not straightforward, because the trials enrolled different patient populations, used different endpoints, and were conducted at different times. Direct head-to-head data do not exist. But the question of which therapy produces the most durable kidney protection will increasingly drive prescribing decisions as nephrologists gain experience with multiple approved options. The ORIGIN 3 final analysis positions TRUTAKNA as a strong contender in that conversation, particularly given the breadth of its endpoint achievement and the consistency of its safety profile across the full two-year follow-up.

Vera Therapeutics also noted that in the first ten weeks following TRUTAKNA's commercial launch, the company generated over 350 patient start forms and is seeing paid claims with encouraging payer policies. Early commercial traction in a newly competitive market is not guaranteed, and the launch momentum suggests the drug is finding its way to patients who need it.

What This Means for Patients and the Field

Approximately 2.5 adults per 100,000 worldwide are diagnosed with IgAN each year, most often between the ages of 30 and 40. These are patients who face the prospect of progressive kidney failure during their most productive decades, with dialysis or transplantation as the eventual outcome if the disease is not controlled. The arrival of multiple disease-modifying therapies with two-year outcome data is a genuine shift in what is possible for this population.

The ORIGIN 3 final analysis is also notable for what it signals about the FDA's evolving approach to IgAN trials. ORIGIN 3 is the first reported Phase 3 IgAN trial to reach alignment with the FDA on an earlier final efficacy analysis, allowing patients randomized to placebo to transition to open-label TRUTAKNA sooner than a standard trial design would permit. That alignment reflects a regulatory posture that takes seriously both the urgency of the unmet need and the ethical dimension of keeping patients on placebo when effective therapy is available.

The supplemental BLA submission planned for Q4 2026 will be the next milestone to watch. If the FDA grants full approval on the timeline Vera Therapeutics is projecting, TRUTAKNA will become the first therapy in the IgAN space to convert accelerated approval to full approval on the basis of two-year eGFR stabilization data. That would be a meaningful regulatory precedent for the field, and a meaningful clinical advance for the patients who have been waiting for it.